Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $3.45 Analyst target: $15.50 Upside: 349.28%
Passage Bio, Inc., a genetic drug company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. The company is headquartered in Philadelphia, Pennsylvania.
See the full interactive analysis & chart →Informational only — not investment advice.